BMA - North Orlando is a medicare approved dialysis facility center in Altamonte Springs, Florida and it has 12 dialysis stations. It is located in Seminole county at 750 S North Lake Blvd Ste 1024, Altamonte Springs, FL, 32701. You can reach out to the office of BMA - North Orlando at (407) 831-7070. This dialysis clinic is managed and/or owned by Fresenius Medical Care. BMA - North Orlando has the following ownership type - Profit. It was first certified by medicare in July, 1996. The medicare id for this facility is 102700 and it accepts patients under medicare ESRD program.
| Name | BMA - North Orlando |
|---|---|
| Location | 750 S North Lake Blvd Ste 1024, Altamonte Springs, Florida |
| No. of Dialysis Stations | 12 |
| Medicare ID | 102700 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 750 S North Lake Blvd Ste 1024, Altamonte Springs, Florida, 32701 | |
| (407) 831-7070 | |
| Not Available |
News Archive
For a glycerol molecule, a measly angstrom's difference in diameter is a road-closed sign: You can't squeeze through unless you are a sleek, water-molecule-sized sports car, say scientists at the University of Illinois at Urbana-Champaign.
One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
› Verified 4 days ago
| NPI Number | 1619089471 |
| Organization Name | Bma North Orlando |
| Doing Business As | Bio-medical Applications Of Florida, Inc. |
| Address | 750 Northlake Blvd Altamonte Springs, Florida, 32701 |
| Phone Number | (407) 831-7070 |
News Archive
For a glycerol molecule, a measly angstrom's difference in diameter is a road-closed sign: You can't squeeze through unless you are a sleek, water-molecule-sized sports car, say scientists at the University of Illinois at Urbana-Champaign.
One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 37 |
News Archive
For a glycerol molecule, a measly angstrom's difference in diameter is a road-closed sign: You can't squeeze through unless you are a sleek, water-molecule-sized sports car, say scientists at the University of Illinois at Urbana-Champaign.
One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 73 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 606 |
| Percentage of adult patients getting regular hemodialysis at the center | |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
For a glycerol molecule, a measly angstrom's difference in diameter is a road-closed sign: You can't squeeze through unless you are a sleek, water-molecule-sized sports car, say scientists at the University of Illinois at Urbana-Champaign.
One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at BMA - North Orlando with elevated calcium levels.
| Patients with hypercalcemia | 78 |
| Hypercalcemia patient months | 660 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | |
| Patients with Serumphosphor | 81 |
| Patients with Serumphosphor less than 3.5 mg/dL | |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | |
| Patients with Serumphosphor greater than 7 mg/dL |
News Archive
For a glycerol molecule, a measly angstrom's difference in diameter is a road-closed sign: You can't squeeze through unless you are a sleek, water-molecule-sized sports car, say scientists at the University of Illinois at Urbana-Champaign.
One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 63 |
| Patient months included in arterial venous fistula and catheter summaries | 434 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
For a glycerol molecule, a measly angstrom's difference in diameter is a road-closed sign: You can't squeeze through unless you are a sleek, water-molecule-sized sports car, say scientists at the University of Illinois at Urbana-Champaign.
One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
For a glycerol molecule, a measly angstrom's difference in diameter is a road-closed sign: You can't squeeze through unless you are a sleek, water-molecule-sized sports car, say scientists at the University of Illinois at Urbana-Champaign.
One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
› Verified 4 days ago